[Click eStocks] "MEKICS Accelerates Global Expansion with Full-Scale Entry into US and Japan Respiratory Care Device Markets" View original image

On July 2, independent research firm ValueFinder analyzed that MEKICS has entered the global commercialization stage by starting shipment of the initial batch of HFT750U (OmniOx series) to the United States.


MEKICS, established in 1998, is a medical device company specializing in respiratory care. The company develops and manufactures ventilators, respiratory care devices, and patient monitors. As of the first quarter of this year, its sales breakdown consists of ventilators at 12.1%, respiratory care devices at 12.1%, patient monitors at 6.3%, and consumables and others at 69.5%.


The company’s business model is characterized by a high proportion of recurring revenue from consumables, which are continuously sold after equipment installation. This structure enables repeated sales as the installed base expands, and is considered a key competitive advantage for the company.


MEKICS has completed the initial production and final quality verification of the HFT750U and will begin shipping products for the U.S. market this month. The product will be supplied sequentially to hospitals and medical institutions through a major local partner with a nationwide medical distribution network in the United States. This supply is based on an exclusive supply agreement signed with the local partner.


The global respiratory care device market is reportedly seeing expanded opportunities for new entrants as supply chains are being reorganized. Following large-scale product recalls by major manufacturers in 2021, ongoing quality issues with certain products have led to increased demand for stable new suppliers.


MEKICS expects that this market environment will have a positive impact on the successful entry of the FDA-certified HFT750U into the U.S. market.


Preparations for entry into the Japanese market are also proceeding smoothly. The company has completed both approval from the Pharmaceuticals and Medical Devices Agency (PMDA) and the final quality verification by its local partner, and is about to begin supply.


Japan is known for its high regulatory standards and long product verification periods in the medical device market. Therefore, securing a local supply base is expected to serve as a major reference for further global market expansion.


In Japan, MEKICS plans to use its local partner’s distribution network for equipment, while consumables with replacement cycles will be supplied directly by the company. Through this strategy, the company aims to expand equipment distribution and secure a stable foundation for recurring revenue.


Chungheon Lee, an analyst at ValueFinder, stated, “The initial shipment to the U.S. signifies that the company has truly entered the commercialization stage based on FDA certification,” and added, “As overseas equipment supply expands, the pace of performance improvement driven by increased consumable sales will also accelerate.”



He further noted, “Once a supply base is established in Japan, MEKICS will be able to diversify its revenue sources centered on the U.S. and Japan. The recurring revenue structure focused on consumables from increased equipment installations will drive mid- to long-term profitability improvement. It is important to pay attention to the performance trend once overseas sales are fully reflected, following the turnaround to operating profit in the first quarter of this year.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing